Memory Impairment Allied to Temporal Lobe Epilepsy and its Deterioration by Phenytoin: A Highlight on Ameliorative Effects of Levetiracetam in Mouse Model

Asher John Mohan; Kamsagara Linganna Krishna

doi:10.1055/s-0038-1656714

International Journal of Epilepsy, Table of Contents

CC BY-NC-ND 4.0 · International Journal of Epilepsy 2018; 05(01): 019-027
DOI: 10.1055/s-0038-1656714

Original Article

Indian Epilepsy Society

Memory Impairment Allied to Temporal Lobe Epilepsy and its Deterioration by Phenytoin: A Highlight on Ameliorative Effects of Levetiracetam in Mouse Model

Asher John Mohan

¹Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysore, Karnataka, India

,

Kamsagara Linganna Krishna

¹Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysore, Karnataka, India

› Author Affiliations

Abstract

Background/Objectives Memory impairment (MI) and epilepsy go hand in hand, mainly in conditions of temporal lobe epilepsy (TLE). This disease comorbidity has been reported to worsen upon treatment. Hence this study aims to evaluate the extent of aggravating effect of phenytoin (PHT) at normal and reduced doses on MI associated with TLE and additionally assesses the protective effect of levetiracetam (LEV) on these adverse effects.

Methods Swiss albino mice of either sex (n = 36) were used for this study in which seizures were induced by intraperitoneal administration of pilocarpine (300 mg/kg i.p.) followed by evaluation of antiepileptic activity by technique of Racine's scale for convulsive scores. Errors (a factor denoting MI) were assessed using radial arm maze. Finally brain biochemical measures of acetylcholinesterase and glutamate along with cresyl violet staining and estimation of total neuronal number of the hippocampus were performed.

Results Exacerbation of MI by PHT was observed, where the extent of MI was found to be lesser in the reduced dose approach (PHTR: 28.50 ± 1.03; p ≤ 0.05). However, this tactic in dose reduction was interfered with the antiepileptic potential of the drug. Attenuation of MI upon combining with LEV, without an interference in the principal treatment, was observed equally in the behavioral and brain aspects of the study (PHTN + LEV: 1.33 ± 0.33 and PHTR + LEV: 1.00 ± 0.17; p ≤ 0.05).

Conclusions The promising effects of LEV could thus aid in proposing a new management remedy for TLE to minimize the adverse effect associated with it.

Keywords

pilocarpine - phenytoin - levetiracetam - antiepileptic drugs

Full Text

References

References
1 Ono T, Galanopoulou AS. Epilepsy and epileptic syndrome. Adv Exp Med Biol 2012; 724: 99-113
2 Zhao F, Kang H, You L, Rastogi P, Venkatesh D, Chandra M. Neuropsychological deficits in temporal lobe epilepsy: a comprehensive review. Ann Indian Acad Neurol 2014; 17 (04) 374-382
3 Al-Mufti F, Claassen J. Neurocritical care: status epilepticus review. Crit Care Clin 2014; 30 (04) 751-764
4 Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disorder 2011; 4 (06) 385-407
5 Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988; 2 (03) 145-181
6 Turski WA, Cavalheiro EA, Schwarz M, Czuczwar SJ, Kleinrok Z, Turski L. Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study. Behav Brain Res 1983; 9 (03) 315-335
7 Goldenberg MM. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. P&T 2010; 35 (07) 392-415
8 Mishra A, Goel RK. Comparative behavioral and neurochemical analysis of phenytoin and valproate treatment on epilepsy induced learning and memory deficit: search for add on therapy. Metab Brain Dis 2015; 30 (04) 951-958
9 Mondadori C, Ducret T, Borkowski J. The memory-enhancing effects of the piracetam-like nootropics are dependent on experimental parameters. Behav Brain Res 1989; 33 (01) 79-82
10 Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat 2008; 4 (03) 507-523
11 Martínez-Granero MA, García-Pérez A, Montañes F. Levetirac-etam as an alternative therapy for Tourette syndrome. Neuropsychiatr Dis Treat 2010; 6: 309-316
12 Sanchez PE, Zhu L, Verret L. et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A 2012; 109 (42) E2895-E2903
13 Wright C, Downing J, Mungall D. et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol 2013; 4: 192
14 Ohmori H, Yamashita K, Hatta T. et al. Effects of low-dose phenytoin administered to newborn mice on developing cerebellum. Neurotoxicol Teratol 1997; 19 (03) 205-211
15 Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 2001; 42 (Suppl. 04) 13-18
16 Furman M. Seizure initiation and propagation in the pilocarpine rat model of temporal lobe epilepsy. J Neurosci 2013; 33 (42) 16409-16411
17 Gupta SK. Drug Screening Methods. 2nd ed.. New Delhi, India: Jaypee Brothers; 2004: 414
18 Vogel HG. Drug Discovery and Evaluation Pharmacological Assays. 2nd ed.. Verlag Berlin Heidelberg: Springer; 2006: 630
19 Ellman GL, Courtney KD, Andres Jr V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95
20 Rahman H, Eswaraiah MC. Simple Spectroscopic Methods for Estimating Brain Neurotransmitters, Antioxidant Enzymes of Laboratory Animals Like Mice: A Review. Hyderabad, India: PharmaTutor Art; 2008: 1244
21 Raju TR, Kutty BM, Sathyaprabha TN, Shanakranarayana RS. Estimation of neurotransmitters in the brain by chromatographic methods. Brain Behav. 2004: 134-141
22 Cresyl Violet Stain for Neuron Somas. Available at: http://www.neurosciencecourses.com/cresyl-violet-stain.html Accessed July 21, 2016
23 Deitch AD, Moses MJ. The Nissl substance of living and fixed spinal ganglion cells. II. An ultraviolet absorption study. J Biophys Biochem Cytol 1957; 3 (03) 449-456
24 West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991; 231 (04) 482-497
25 Buckmaster PS, Haney MM. Factors affecting outcomes of pilo-carpine treatment in a mouse model of temporal lobe epilepsy. Epilepsy Res 2012; 102 (03) 153-159
26 Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia 2009; 50 (03) 387-397
27 Penley SC, Gaudet CM, Threlkeld SW. Use of an eight-arm radial water maze to assess working and reference memory following neonatal brain injury. J Vis Exp 2013; 82 (82) 50940
28 McDonald CR, Ahmadi ME, Hagler DJ. et al. Diffusion tensor imaging correlates of memory and language impairments in temporal lobe epilepsy. Neurology 2008; 71 (23) 1869-1876
29 Motamedi GK, Meador KJ. Antiepileptic drugs and memory. Epilepsy Behav 2004; 5 (04) 435-439
30 Witt JA, Helmstaedter C. Monitoring the cognitive effects of antiepileptic pharmacotherapy—approaching the individual patient. Epilepsy Behav 2013; 26 (03) 450-456
31 Greener M. Beyond seizures: understanding cognitive deficits in epilepsy. Prog Neurol Psychiatry 2013; 17 (03) 31-32
32 Hasselmo ME. The role of acetylcholine in learning and memory. Curr Opin Neurobiol 2006; 16 (06) 710-715
33 Saraswathy GR, Maheswari E, Santhrani T. Protective effect of alpha lipoic acid against phenytoin induced behavioral abnormalities in rats. J Mol Biomark Diagn 2015; 6 (04) 241
34 Pestana RR, Kinjo ER, Hernandes MS, Britto LR. Reactive oxygen species generated by NADPH oxidase are involved in neurodegeneration in the pilocarpine model of temporal lobe epilepsy. Neurosci Lett 2010; 484 (03) 187-191
35 Tabet N. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!. Age Ageing 2006; 35 (04) 336-338
36 Easton A, Douchamps V, Eacott M, Lever C. A specific role for septohippocampal acetylcholine in memory?. Neuropsychologia 2012; 50 (13) 3156-3168
37 Cho CH. New mechanism for glutamate hypothesis in epilepsy. Front Cell Neurosci 2013; 7: 127
38 Muhlert N, Atzori M, De Vita E. et al. Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions. J Neurol Neurosurg Psychiatry 2014; 85 (08) 833-839
39 Gambardella A, Valentino P, Labate A. et al. Temporal lobe epilepsy as a unique manifestation of multiple sclerosis. Can J Neurol Sci 2003; 30 (03) 228-232
40 McEntee WJ, Crook TH. Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology (Berl) 1993; 111 (04) 391-401
41 Lee CY, Chen CC, Liou HH. Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus. Br J Pharmacol 2009; 158 (07) 1753-1762